Pharmather Holdings Ltd
CNSX:PHRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharmather Holdings Ltd
Income from Continuing Operations
Pharmather Holdings Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pharmather Holdings Ltd
CNSX:PHRM
|
Income from Continuing Operations
-CA$1.5m
|
CAGR 3-Years
28%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Income from Continuing Operations
$120m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Income from Continuing Operations
-$345.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-36%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Income from Continuing Operations
-CA$5.4m
|
CAGR 3-Years
44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Income from Continuing Operations
-CA$47.7m
|
CAGR 3-Years
-84%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-17%
|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Income from Continuing Operations
$17.4m
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
20%
|
|
Pharmather Holdings Ltd
Glance View
PharmaTher Holdings Ltd. is a specialty psychedelic pharmaceutical company, which engages in the research, development and commercialization of ketamine and novel microneedle patches for delivering psychedelics to treat neuropsychiatric, neurodegenerative, and pain disorders. The company is headquartered in Toronto, British Columbia. The company went IPO on 2020-10-09. The firm is focused on the research, development and commercialization uses, formulations and delivery methods of psychedelics to treat mental illness, neurological and pain disorders. The firm's product pipeline targets the use of ketamine to treat Parkinson’s disease, depression, amyotrophic lateral sclerosis (Lou Gehrig’s disease) and pain. The firm is also focused on developing a microneedle patch to deliver ketamine and other psychedelics, such as psilocybin, N, N-Dimethyltryptamine (DMT), Lysergic acid diethylamide (LSD) and 3,4-Methylenedioxymethamphetamine (MDMA).
See Also
What is Pharmather Holdings Ltd's Income from Continuing Operations?
Income from Continuing Operations
-1.5m
CAD
Based on the financial report for May 31, 2025, Pharmather Holdings Ltd's Income from Continuing Operations amounts to -1.5m CAD.
What is Pharmather Holdings Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-40%
Over the last year, the Income from Continuing Operations growth was 51%. The average annual Income from Continuing Operations growth rates for Pharmather Holdings Ltd have been 28% over the past three years , -40% over the past five years .
